{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T12:33:40Z","timestamp":1786365220403,"version":"build-2736575974"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,10]]},"DOI":"10.7759\/cureus.114260","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T12:21:51Z","timestamp":1786364511000},"source":"Crossref","is-referenced-by-count":0,"title":["Comparative Efficacy of Interleukin Inhibitors and JAK Inhibitors in Moderate to Severe Plaque Psoriasis"],"prefix":"10.7759","author":[{"given":"Alexandra","family":"Daily","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"London","family":"Danchulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiarra","family":"Krulikowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brittany","family":"Shectman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne I","family":"Riskin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2017.07.004","article-title":"Psoriasis pathogenesis and the development of novel targeted immune therapies","volume":"140","author":"Hawkes JE","year":"2017","unstructured":"Hawkes JE, Chan TC, Krueger JG. Psoriasis pathogenesis and the development of novel targeted immune therapies. J Allergy Clin Immunol. 2017, 140:645-53. 10.1016\/j.jaci.2017.07.004","journal-title":"J Allergy Clin Immunol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17053","article-title":"Addressing challenges associated with long-term topical treatment and benefits of proactive management in patients with psoriasis","volume":"35 Suppl 1","author":"Lebwohl M","year":"2021","unstructured":"Lebwohl M, Tha\u00e7i D, Warren RB. Addressing challenges associated with long-term topical treatment and benefits of proactive management in patients with psoriasis. J Eur Acad Dermatol Venereol. 2021, 35 Suppl 1:35-41. 10.1111\/jdv.17053","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljad035","article-title":"Bimekizumab maintenance of response through 3\u2005years in patients with moderate-to-severe plaque psoriasis: results from the BE BRIGHT open-label extension trial","volume":"188","author":"Strober B","year":"2023","unstructured":"Strober B, Tada Y, Mrowietz U, et al.. Bimekizumab maintenance of response through 3\u2005years in patients with moderate-to-severe plaque psoriasis: results from the BE BRIGHT open-label extension trial. Br J Dermatol. 2023, 188:749-59. 10.1093\/bjd\/ljad035","journal-title":"Br J Dermatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jare.2018.09.003","article-title":"Risk of serious infection among patients receiving biologics for chronic inflammatory diseases: usefulness of administrative data","volume":"15","author":"Quartuccio L","year":"2019","unstructured":"Quartuccio L, Zabotti A, Del Zotto S, Zanier L, De Vita S, Valent F. Risk of serious infection among patients receiving biologics for chronic inflammatory diseases: usefulness of administrative data. J Adv Res. 2019, 15:87-93. 10.1016\/j.jare.2018.09.003","journal-title":"J Adv Res"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21207488","article-title":"New treatment addressing the pathogenesis of psoriasis","volume":"21","author":"Tokuyama M","year":"2020","unstructured":"Tokuyama M, Mabuchi T. New treatment addressing the pathogenesis of psoriasis. Int J Mol Sci. 2020, 21:7488. 10.3390\/ijms21207488","journal-title":"Int J Mol Sci"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13435","article-title":"First-in-human study of deucravacitinib: a selective, potent, allosteric small-molecule inhibitor of tyrosine kinase 2","volume":"16","author":"Catlett IM","year":"2023","unstructured":"Catlett IM, Aras U, Hansen L, Liu Y, Bei D, Girgis IG, Murthy B. First-in-human study of deucravacitinib: a selective, potent, allosteric small-molecule inhibitor of tyrosine kinase 2. Clin Transl Sci. 2023, 16:151-64. 10.1111\/cts.13435","journal-title":"Clin Transl Sci"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s40801-023-00359-1","article-title":"Dermatology life quality index in patients with psoriasis treated with biologic versus non-biologic treatment in Malaysia: a retrospective cross-sectional study","volume":"10","author":"Robinson S","year":"2023","unstructured":"Robinson S, Moon TM, Eng TK, et al.. Dermatology life quality index in patients with psoriasis treated with biologic versus non-biologic treatment in Malaysia: a retrospective cross-sectional study. Drugs Real World Outcomes. 2023, 10:291-8. 10.1007\/s40801-023-00359-1","journal-title":"Drugs Real World Outcomes"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s10753-023-01915-1","article-title":"The use of microbial modifying therapies to prevent psoriasis exacerbation and associated cardiovascular comorbidity","volume":"47","author":"Reali E","year":"2024","unstructured":"Reali E, Caliceti C, Lorenzini A, Rizzo P. The use of microbial modifying therapies to prevent psoriasis exacerbation and associated cardiovascular comorbidity. Inflammation. 2024, 47:13-29. 10.1007\/s10753-023-01915-1","journal-title":"Inflammation"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20827","article-title":"Bimekizumab for the treatment of moderate-to-severe plaque psoriasis: efficacy, safety, pharmacokinetics, pharmacodynamics and transcriptomics from a phase IIa, randomized, double-blind multicentre study","volume":"186","author":"Oliver R","year":"2022","unstructured":"Oliver R, Krueger JG, Glatt S, et al.. Bimekizumab for the treatment of moderate-to-severe plaque psoriasis: efficacy, safety, pharmacokinetics, pharmacodynamics and transcriptomics from a phase IIa, randomized, double-blind multicentre study. Br J Dermatol. 2022, 186:652-63. 10.1111\/bjd.20827","journal-title":"Br J Dermatol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2020.0723","article-title":"Efficacy and safety of continuous risankizumab therapy vs treatment withdrawal in patients with moderate to severe plaque psoriasis: a phase 3 randomized clinical trial","volume":"156","author":"Blauvelt A","year":"2020","unstructured":"Blauvelt A, Leonardi CL, Gooderham M, et al.. Efficacy and safety of continuous risankizumab therapy vs treatment withdrawal in patients with moderate to severe plaque psoriasis: a phase 3 randomized clinical trial. JAMA Dermatol. 2020, 156:649-58. 10.1001\/jamadermatol.2020.0723","journal-title":"JAMA Dermatol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2024.103649","article-title":"Tyrosine kinase 2 inhibitors in autoimmune diseases","volume":"23","author":"Ramakrishna C","year":"2024","unstructured":"Ramakrishna C, Mason A, Edwards CJ. Tyrosine kinase 2 inhibitors in autoimmune diseases. Autoimmun Rev. 2024, 23:103649. 10.1016\/j.autrev.2024.103649","journal-title":"Autoimmun Rev"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106642","article-title":"Deucravacitinib is an allosteric TYK2 protein kinase inhibitor FDA-approved for the treatment of psoriasis","volume":"189","author":"Roskoski R Jr","year":"2023","unstructured":"Roskoski R Jr. Deucravacitinib is an allosteric TYK2 protein kinase inhibitor FDA-approved for the treatment of psoriasis. Pharmacol Res. 2023, 189:106642. 10.1016\/j.phrs.2022.106642","journal-title":"Pharmacol Res"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2023.07.1024","article-title":"Long-term safety and efficacy of risankizumab for the treatment of moderate-to-severe plaque psoriasis: interim analysis of the LIMMitless open-label extension trial up to 5\u00a0years of follow-up","volume":"89","author":"Papp KA","year":"2023","unstructured":"Papp KA, Blauvelt A, Puig L, et al.. Long-term safety and efficacy of risankizumab for the treatment of moderate-to-severe plaque psoriasis: interim analysis of the LIMMitless open-label extension trial up to 5\u00a0years of follow-up. J Am Acad Dermatol. 2023, 89:1149-58. 10.1016\/j.jaad.2023.07.1024","journal-title":"J Am Acad Dermatol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00126-4","article-title":"Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial","volume":"397","author":"Gordon KB","year":"2021","unstructured":"Gordon KB, Foley P, Krueger JG, et al.. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial. Lancet. 2021, 397:475-86. 10.1016\/S0140-6736(21)00126-4","journal-title":"Lancet"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-024-01224-x","article-title":"Deucravacitinib improves patient-reported outcomes in patients with moderate to severe psoriasis: results from the phase 3 randomized POETYK PSO-1 and PSO-2 trials","volume":"14","author":"Armstrong AW","year":"2024","unstructured":"Armstrong AW, Augustin M, Beaumont JL, et al.. Deucravacitinib improves patient-reported outcomes in patients with moderate to severe psoriasis: results from the phase 3 randomized POETYK PSO-1 and PSO-2 trials. Dermatol Ther (Heidelb). 2024, 14:2235-48. 10.1007\/s13555-024-01224-x","journal-title":"Dermatol Ther (Heidelb)"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19925","article-title":"Deucravacitinib in moderate-to-severe plaque psoriasis: pooled safety and tolerability over 52\u2009weeks from two phase 3 trials (POETYK PSO-1 and PSO-2)","volume":"38","author":"Strober B","year":"2024","unstructured":"Strober B, Blauvelt A, Warren RB, et al.. Deucravacitinib in moderate-to-severe plaque psoriasis: pooled safety and tolerability over 52\u2009weeks from two phase 3 trials (POETYK PSO-1 and PSO-2). J Eur Acad Dermatol Venereol. 2024, 38:1543-54. 10.1111\/jdv.19925","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2024.2371045","article-title":"Deucravacitinib onset of action and maintenance of response in phase 3 plaque psoriasis trials","volume":"35","author":"Korman NJ","year":"2024","unstructured":"Korman NJ, Warren RB, Bagel J, et al.. Deucravacitinib onset of action and maintenance of response in phase 3 plaque psoriasis trials. J Dermatolog Treat. 2024, 35:2371045. 10.1080\/09546634.2024.2371045","journal-title":"J Dermatolog Treat"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.20553","article-title":"Deucravacitinib in plaque psoriasis: four-year safety and efficacy results from the Phase 3 POETYK PSO-1, PSO-2 and long-term extension trials","volume":"39","author":"Armstrong AW","year":"2025","unstructured":"Armstrong AW, Lebwohl M, Warren RB, et al.. Deucravacitinib in plaque psoriasis: four-year safety and efficacy results from the Phase 3 POETYK PSO-1, PSO-2 and long-term extension trials. J Eur Acad Dermatol Venereol. 2025, 39:1336-51. 10.1111\/jdv.20553","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-023-02477-2","article-title":"Efficacy, safety, patient experience, and tolerability of risankizumab administered by on-body injector for moderate to severe Crohn\u2019s disease","volume":"40","author":"Loftus EV Jr","year":"2023","unstructured":"Loftus EV Jr, Griffith J, Neimark E, et al.. Efficacy, safety, patient experience, and tolerability of risankizumab administered by on-body injector for moderate to severe Crohn\u2019s disease. Adv Ther. 2023, 40:2311-25. 10.1007\/s12325-023-02477-2","journal-title":"Adv Ther"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2022.04.023","article-title":"Patient preferences for benefits, risks, and administration route of hypomethylating agents in myelodysplastic syndromes","volume":"22","author":"Zeidan AM","year":"2022","unstructured":"Zeidan AM, Tsai JH, Karimi M, et al.. Patient preferences for benefits, risks, and administration route of hypomethylating agents in myelodysplastic syndromes. Clin Lymphoma Myeloma Leuk. 2022, 22:e853-66. 10.1016\/j.clml.2022.04.023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-023-01089-6","article-title":"Evaluating treatment choice in patients with moderate to severe psoriasis in the United States: results from a US patient survey","volume":"14","author":"Armstrong AW","year":"2024","unstructured":"Armstrong AW, Jayade S, Rege S, et al.. Evaluating treatment choice in patients with moderate to severe psoriasis in the United States: results from a US patient survey. Dermatol Ther (Heidelb). 2024, 14:421-39. 10.1007\/s13555-023-01089-6","journal-title":"Dermatol Ther (Heidelb)"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-024-01159-3","article-title":"Unmet needs and treatment preference of systemic treatments for moderate-to-severe psoriasis from the perspectives of patients and dermatologists in China","volume":"14","author":"Kuang Y","year":"2024","unstructured":"Kuang Y, Li Y, Lv C, et al.. Unmet needs and treatment preference of systemic treatments for moderate-to-severe psoriasis from the perspectives of patients and dermatologists in China. Dermatol Ther (Heidelb). 2024, 14:1245-57. 10.1007\/s13555-024-01159-3","journal-title":"Dermatol Ther (Heidelb)"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31713-6","article-title":"Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials","volume":"392","author":"Gordon KB","year":"2018","unstructured":"Gordon KB, Strober B, Lebwohl M, et al.. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet. 2018, 392:650-61. 10.1016\/S0140-6736(18)31713-6","journal-title":"Lancet"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-024-01293-y","article-title":"Matching-adjusted indirect comparison of risankizumab versus deucravacitinib in patients with moderate-to-severe plaque psoriasis","volume":"14","author":"Armstrong AW","year":"2024","unstructured":"Armstrong AW, Soliman AM, Gisondi P, Fang S, Patel M, Strober B. Matching-adjusted indirect comparison of risankizumab versus deucravacitinib in patients with moderate-to-severe plaque psoriasis. Dermatol Ther (Heidelb). 2024, 14:3071-81. 10.1007\/s13555-024-01293-y","journal-title":"Dermatol Ther (Heidelb)"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-004007","article-title":"Long-term safety and efficacy of upadacitinib versus adalimumab in patients with rheumatoid arthritis: 5-year data from the phase 3, randomised SELECT-COMPARE study","volume":"10","author":"Fleischmann R","year":"2024","unstructured":"Fleischmann R, Swierkot J, Penn SK, et al.. Long-term safety and efficacy of upadacitinib versus adalimumab in patients with rheumatoid arthritis: 5-year data from the phase 3, randomised SELECT-COMPARE study. RMD Open. 2024, 10:e004007. 10.1136\/rmdopen-2023-004007","journal-title":"RMD Open"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljae404","article-title":"Efficacy and safety of upadacitinib versus dupilumab in adults and adolescents with moderate-to-severe atopic dermatitis: week 16 results of an open-label randomized efficacy assessor-blinded head-to-head phase IIIb\/IV study (Level Up)","volume":"192","author":"Silverberg JI","year":"2024","unstructured":"Silverberg JI, Bunick CG, Hong HC, et al.. Efficacy and safety of upadacitinib versus dupilumab in adults and adolescents with moderate-to-severe atopic dermatitis: week 16 results of an open-label randomized efficacy assessor-blinded head-to-head phase IIIb\/IV study (Level Up). Br J Dermatol. 2024, 192:36-45. 10.1093\/bjd\/ljae404","journal-title":"Br J Dermatol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-023-00977-1","article-title":"Matching-adjusted indirect comparison of the long-term efficacy of deucravacitinib versus adalimumab for moderate to severe plaque psoriasis","volume":"13","author":"Armstrong AW","year":"2023","unstructured":"Armstrong AW, Park SH, Patel V, Hogan M, Wang WJ, Davidson D, Chirikov V. Matching-adjusted indirect comparison of the long-term efficacy of deucravacitinib versus adalimumab for moderate to severe plaque psoriasis. Dermatol Ther (Heidelb). 2023, 13:2589-603. 10.1007\/s13555-023-00977-1","journal-title":"Dermatol Ther (Heidelb)"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/433603-comparative-efficacy-of-interleukin-inhibitors-and-jak-inhibitors-in-moderate-to-severe-plaque-psoriasis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T12:21:51Z","timestamp":1786364511000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/433603-comparative-efficacy-of-interleukin-inhibitors-and-jak-inhibitors-in-moderate-to-severe-plaque-psoriasis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,10]]},"references-count":27,"URL":"https:\/\/doi.org\/10.7759\/cureus.114260","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,10]]}}}